Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

8.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
3.9K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

11.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.5K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic landscape, key transcriptional regulators, and in vivo identification of human Tr1 cells.

Science advances·2026
Same author

Detecting and reconstructing breakage-fusion-bridge cycles from long-read sequencing using BFBArchitect.

Bioinformatics (Oxford, England)·2026
Same author

A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study.

Journal of the National Cancer Institute·2026
Same author

Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors.

bioRxiv : the preprint server for biology·2026
Same author

The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Applications of transcranial focused ultrasound for primary brain tumors.

Neuro-oncology advances·2026

Related Experiment Video

Updated: Jun 4, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Engineered extrachromosomal oncogene amplifications promote tumorigenesis.

Davide Pradella1, Minsi Zhang1,2, Rui Gao1,3

  • 1Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Nature
|December 18, 2024
PubMed
Summary

Scientists engineered large focal gene amplifications using extrachromosomal DNAs (ecDNAs) in cells and mice. This breakthrough enables studying cancer-associated mutations and developing new preclinical cancer models.

More Related Videos

Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens
03:55

Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens

Published on: July 12, 2024

1.2K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.5K

Related Experiment Videos

Last Updated: Jun 4, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens
03:55

Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens

Published on: July 12, 2024

1.2K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.5K

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • Focal gene amplifications are common cancer mutations.
  • Engineering these amplifications in model systems is difficult.

Purpose of the Study:

  • To develop a general strategy for engineering large focal gene amplifications using extrachromosomal DNAs (ecDNAs).
  • To investigate the role of ecDNA-mediated amplifications in tumorigenesis.
  • To create new preclinical models for cancer research.

Main Methods:

  • Engineered large focal amplifications mediated by ecDNAs in a spatiotemporally controlled manner.
  • Coupled ecDNA formation with selectable markers to track ecDNA dynamics.
  • Generated mice with Cre-inducible Myc- and Mdm2-containing ecDNAs.
  • Demonstrated ecDNA-driven tumor formation in a mouse model.

Main Results:

  • Successfully engineered large focal amplifications using ecDNAs in cells and mice.
  • Observed spontaneous ecDNA accumulation in primary cells, promoting proliferation, immortalization, and transformation.
  • Showed Mdm2-containing ecDNAs promote hepatocellular carcinoma formation in mice.

Conclusions:

  • The developed strategy enables controlled engineering of large focal gene amplifications via ecDNAs.
  • This approach provides insights into ecDNA's role in tumorigenesis.
  • The method is valuable for studying ecDNA biology and developing preclinical cancer models.